|
This program provides brand name medications at no or low cost.
|
| Pharmaceutical Company |
Abraxis Oncology |
| Program Name |
Abraxis Patient Access Program |
| Program Address |
6900 College Blvd, Suite 1000
Overland Park, KS 66211 |
| Phone Number |
800-564-0216, opt 3
|
| Fax Number |
866-242-4141 |
| Medications on Program |
Abraxane for Injectable Suspension 100mg (paclitaxel protein-bound particles for injectable suspension)
|
| Application Forms |
Abraxis Patient Access Program
|
On-line Application
|
No on-line application available at this time |
| Web Site |
Click to go to program's web site |
| Eligibility Guidelines and Notes |
The patient must be uninsured or underinsured and have a gross annual household income at or below $100,000. Medication must be used for medically appropriate condition. The patient must also be permanently residing in the US or US territories. Patients who have insurance and meet the other guidelines will be given assistance after a denied claim and an unsuccessful appeal.Applicants may apply on line through the link at http://www.abraxane.com/professional/reimbursement.aspx and also create an appeal letter on line at https://www.abraxisoncology.com/arc_appeals.aspx
|
| Application Process |
Anyone requesting assistance can call to request a faxed application or download it from the website. The application will be faxed out. The completed application can be faxed or mailed back.
The doctor is notified of acceptance or denial. The decision is usually made within 2-3 business days. The medication is shipped within 3-5 business days.
|
| Application Requirements |
The doctor must fill out a section and sign the application. The patient must fill out a section and sign the application.
|
| Program Details |
The medication is sent one cycle at a time to the doctor's office for administration. For uninsured patients the medication is sent out before the treatment, for insured patients the medication replaced to the doctor's office. Every 6 months a new application is needed.
|
| Last Updated |
November 13, 2009 |
